The Sage Group Represents VAL401 - A Unique Formulation of Respiridone for Cancer Supportive Care
The Sage Group is working with UK-based ValiRx, which is developing a unique, patented, cancer supportive care product, VAL401, for which it seeks a global or regional partner. VAL401 is the first, and as far as we know, only cancer supportive care product to use risperidone in a unique lipid-based formulation with rumenic acid, an essential and functional component of the combination, specifically to improve the quality of life of late-stage cancer patients thus contributing